Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Male
Prostate Cancer
Male
Prostate Cancer
Trial Information
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands
Inclusion Criteria:
- Patients with advanced hormone-dependent prostate carcinoma that are eligible for
hormone therapy
Exclusion Criteria:
- Patients with a contraindication for prescription of Firmagon®
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To estimate the progression-free survival (PFS) failure rate
Outcome Time Frame:
Maximum 3 years
Safety Issue:
No
Principal Investigator
Clinical Development Support
Investigator Role:
Study Director
Investigator Affiliation:
Ferring Pharmaceuticals
Authority:
Netherlands: Ministry of Health, Welfare and Sport
Study ID:
FE200486 CS46
NCT ID:
NCT01215526
Start Date:
October 2010
Completion Date:
December 2015
Related Keywords:
- Prostate Cancer
- Prostatic Neoplasms
Name | Location |
|---|
